Chairman
Ethos Discovery
Dr. Khanna is a graduate of the Western College of Veterinary Medicine. He then received specialty training in the fields of veterinary internal medicine and oncology, first at the Ontario Veterinary College, University of Guelph, and then at the University of Minnesota. Dr. Khanna is a Diplomate of the American College of Veterinary Internal Medicine (Oncology). Following this clinical specialization, Dr. Khanna received a PhD in Pathobiology from the University of Minnesota and then completed a post-doctoral fellowship with Dr. Lee Helman in the Pediatric Oncology Branch of the National Cancer Institute in Bethesda, Maryland. He was recently awarded honorary membership as a Diplomate of the American College Veterinary Pathology.
Dr. Khanna continued his work at the National Cancer Institute as the Head of the Pediatric Oncology Branch’s Tumor and Metastasis Biology Section and Director of the Center for Cancer Research, Comparative Oncology Program. In 2011, Dr. Khanna was granted full tenure and promoted to the position of Senior Investigator at the National Cancer Institute. His research interests and responsibilities focused on the problem of cancer metastasis and the development of new options to treat patients with metastasis. He was an active clinician within his referral oncology practice, The Oncology Service, based in the greater Washington, D.C. area, until 2021. He is also the founder of Animal Clinical Investigation, a contract research company involved in complex medical problems seen in pets.
Dr. Khanna is the immediate former president of the American College of Veterinary Internal Medicine in Oncology, the chair of the Children’s Oncology Group Bone Biology Subcommittee, and the Director of the SARC (Sarcoma Alliance for Research through Collaboration) Developmental Therapeutics Committee. Dr. Khanna is a founding member of the Canine Comparative Oncology and Genomics Consortium.
Disclosure information not submitted.
Ethos PUSH: Finding a Cure for Hemangiosarcoma
Friday, October 25, 2024
1:30 PM – 1:50 PM
Novel Therapeutic Approaches for HSA
Friday, October 25, 2024
4:30 PM – 5:30 PM
Panel Discussion: Hemangiosarcoma
Friday, October 25, 2024
5:30 PM – 6:00 PM